Report cover image

Dengue Vaccine Market Size, Share & Trends Analysis Report By Product (Dengvaxia, Qdenga), By End-user (Government & Public Health Agencies, Hospitals & Specialty Clinics), By Region, And Segment Forecasts, 2025 - 2033

Publisher Grand View Research
Published Sep 17, 2025
Length 150 Pages
SKU # GV20471071

Description

Dengue Vaccine Market Summary

The global dengue vaccine market size was estimated at USD 423.18 million in 2024 and is projected to reach USD 1,618.61 million by 2033, growing at a CAGR of 13.73% from 2025 to 2033. The increasing prevalence of dengue fever across tropical and subtropical regions drives strong demand for effective vaccines.

The increasing urbanization and population density create favorable conditions for Aedes mosquitoes, the primary carriers of the virus. The increasing frequency of outbreaks highlights urgent preventive needs, as seen in April 2025, when the World Stock Market reported Brazil had registered 1,010,833 probable cases, 668 confirmed deaths, and 724 under investigation, with São Paulo leading at 585,902 cases. The incidence rate was 475.5 per 100,000, lower than 1,881 per 100,000 in 2024. The increasing awareness among healthcare providers and patients, combined with advances in research, greater accessibility in clinics, and stronger pharmaceutical collaborations, accelerates vaccine adoption and supports global dengue control efforts.

In July 2025, KFF Health News reported a sharp rise in dengue cases across the contiguous United States. The number of new infections reached approximately 3,700, nearly doubling from about 2,050 cases in 2023. Of these, 105 cases were confirmed to be locally transmitted in California, Florida, and Texas, signaling a concerning trend in domestic spread. Historically, dengue infections in the U.S. were mostly travel-related, but the rising local transmission indicates that the Aedes aegypti mosquito has expanded its presence. This surge reflects changing environmental conditions and highlights growing risks for communities that previously faced minimal exposure to dengue. The sudden escalation of cases underscores an urgent need for preventive strategies, including vaccination, mosquito control, and improved monitoring.

Global Dengue Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global dengue vaccine market report based on product, end-user, and region:
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Dengvaxia
  • Qdenga
  • Others
  • End-user Outlook (Revenue, USD Million, 2021 - 2033)
  • Government & Public Health Agencies
  • Hospitals & Specialty Clinics
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

150 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. End User
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Dengue Vaccine Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Dengue Vaccine Market: Product Business Analysis
4.1. Product Market Share, 2024 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Dengvaxia
4.4.1. Dengvaxia Market, 2021 - 2033 (USD Million)
4.5. Qdenga
4.5.1. Qdenga Market, 2021 - 2033 (USD Million)
4.6. Others
4.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. Dengue Vaccine Market: End User Business Analysis
5.1. End User Market Share, 2024 & 2033
5.2. End User Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by End User, 2021 to 2033 (USD Million)
5.4. Government & Public Health Agencies
5.4.1. Government & Public Health Agencies Market, 2021 - 2033 (USD Million)
5.5. Hospitals & Specialty Clinics
5.5.1. Hospitals & Specialty Clinics Market, 2021 - 2033 (USD Million)
5.6. Others
5.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. Dengue Vaccine Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
6.4. North America
6.4.1. North America Dengue Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. U.S. Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. U.S. Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. Mexico Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Europe
6.5.1. Europe Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. Uk Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. Germany Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. France Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Italy Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Target Disease Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. Spain Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Target Disease Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Denmark Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Target Disease Prevalence
6.5.8.3. Regulatory Framework
6.5.8.4. Reimbursement Framework
6.5.8.5. Sweden Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Target Disease Prevalence
6.5.9.3. Regulatory Framework
6.5.9.4. Reimbursement Framework
6.5.9.5. Norway Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. India Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Australia Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Framework
6.6.6.5. South Korea Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Target Disease Prevalence
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Framework
6.6.7.5. Thailand Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Latin America
6.7.1. Latin America Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Target Disease Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. Japan Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. China Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Target Disease Prevalence
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Framework
6.8.2.5. South Africa Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Target Disease Prevalence
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Framework
6.8.3.5. Saudi Arabia Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Target Disease Prevalence
6.8.4.3. Regulatory Framework
6.8.4.4. Reimbursement Framework
6.8.4.5. UAE Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Target Disease Prevalence
6.8.5.3. Regulatory Framework
6.8.5.4. Reimbursement Framework
6.8.5.5. Kuwait Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Sanofi
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Takeda Pharmaceutical Company Limited
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us